Email : info@gapsos.com
Contact : (321) 445-1969

HIV AND HTLV1 ASSOCIATED LYMPHOMA & IMMUNOTHERAPY

Abstract

People with HIV infections are at increased risk for lymphoma. It is a disease in which malignant cells form in the lymphatic system of patients who have acquired immunodeficiency syndrome. The use of highly active anti-retroviral therapy (HAART) to treat HIV has helped patients to better tolerate treatments such as chemo and immunotherapy. Targeted immunotherapies are the evolving therapies where drugs that block the growth and spread of the cancer by interfering with specific molecules that are involved in carcinogenesis. It is a treatment alternative to chemotherapy and radiation in already immuno compromised HIV patients. In this paper, we will discuss the current trends in various immunotherapies and their target molecules involved in the proliferation of the disease.

Download Pdf